Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.

Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK.

Med Decis Making. 2018 Apr;38(1_suppl):9S-23S. doi: 10.1177/0272989X17700624.

2.

Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model.

Schechter CB, Near AM, Jayasekera J, Chandler Y, Mandelblatt JS.

Med Decis Making. 2018 Apr;38(1_suppl):66S-77S. doi: 10.1177/0272989X17698685.

3.

Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age.

Burnside ES, Lee SJ, Bennette C, Near AM, Alagoz O, Huang H, van den Broek JJ, Kim JY, Ergun MA, van Ravesteyn NT, Stout NK, de Koning HJ, Mandelblatt JS.

MDM Policy Pract. 2017 Jul;2. doi: 10.1177/2381468317717982. Epub 2017 Jul 8.

4.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

5.

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.

Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN; Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23.

6.

Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.

Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS, Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS.

J Oncol Pract. 2016 Jan;12(1):59, e1-13. doi: 10.1200/JOP.2015.004838.

7.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA.

Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.

8.

Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program.

van Ravesteyn NT, van Lier L, Schechter CB, Ekwueme DU, Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Mandelblatt JS, de Koning HJ.

Am J Prev Med. 2015 May;48(5):535-42. doi: 10.1016/j.amepre.2014.11.010.

9.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289. Print 2014 Nov.

10.

Sweden SimSmoke: the effect of tobacco control policies on smoking and snus prevalence and attributable deaths.

Near AM, Blackman K, Currie LM, Levy DT.

Eur J Public Health. 2014 Jun;24(3):451-8. doi: 10.1093/eurpub/ckt178. Epub 2013 Nov 27.

11.

Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention.

Mandelblatt J, van Ravesteyn N, Schechter C, Chang Y, Huang AT, Near AM, de Koning H, Jemal A.

Cancer. 2013 Jul 15;119(14):2541-8. doi: 10.1002/cncr.28087. Epub 2013 Apr 26.

12.

Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality.

Chang Y, Schechter CB, van Ravesteyn NT, Near AM, Heijnsdijk EA, Adams-Campbell L, Levy D, de Koning HJ, Mandelblatt JS.

Breast Cancer Res Treat. 2012 Dec;136(3):823-35. doi: 10.1007/s10549-012-2274-3. Epub 2012 Oct 27.

13.

Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.

van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, Nelson HD, Mandelblatt JS, de Koning HJ.

Ann Intern Med. 2012 May 1;156(9):609-17. doi: 10.7326/0003-4819-156-9-201205010-00002.

14.

Using Simulation Modeling to Inform Strategies to Reduce Breast Cancer Mortality in Black Women in the District of Columbia.

Near AM, Mandelblatt JS, Schechter CB, Stoto MA.

Epidemiol Res Int. 2012 Apr 26;2012(2012). pii: 241340.

15.

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.

Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A; Ovarian Cancer Association Consortium.

Lancet Oncol. 2012 Apr;13(4):385-94. doi: 10.1016/S1470-2045(11)70404-1. Epub 2012 Feb 22.

16.

Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States.

van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EA, Stoto MA, Draisma G, de Koning HJ, Mandelblatt JS.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):112-22. doi: 10.1158/1055-9965.EPI-10-0944. Epub 2010 Nov 30.

17.

Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort.

Near AM, Wu AH, Templeman C, Van Den Berg DJ, Doherty JA, Rossing MA, Goode EL, Cunningham JM, Vierkant RA, Fridley BL, Chenevix-Trench G, Webb PM, Kjær SK, Hogdall E, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Schildkraut JM, Moorman PG, Palmieri RT, Ness RB, Moysich K, Cramer DW, Terry KL, Vitonis AF, Pike MC, Berchuck A, Pearce CL; Ovarian Cancer Association Consortium; Australian Cancer Study (Ovarian Cancer) (ACS); Australian Ovarian Cancer Study Group (AOCS).

Fertil Steril. 2011 Jan;95(1):40-5. doi: 10.1016/j.fertnstert.2010.06.059. Epub 2010 Aug 17.

18.

Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.

Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, Rossing MA, Whittemore AS, McGuire V, DiCioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens LR, Ness RB, Moysich KB, Edwards R, Jennison E, Kjaer SK, Hogdall E, Hogdall CK, Goode EL, Sellers TA, Vierkant RA, Cunningham JM, Schildkraut JM, Berchuck A, Moorman PG, Iversen ES, Cramer DW, Terry KL, Vitonis AF, Titus-Ernstoff L, Song H, Pharoah PD, Spurdle AB, Anton-Culver H, Ziogas A, Brewster W, Galitovskiy V, Chenevix-Trench G; Australian Cancer Study; Australian Ovarian Cancer Study Group.

Br J Cancer. 2009 Jan 27;100(2):412-20. doi: 10.1038/sj.bjc.6604820. Epub 2009 Jan 6. Erratum in: Br J Cancer. 2009 Nov 17;101(10):1805. Cunningham, J C [corrected to Cunningham, J M].

19.

Comprehensive evaluation of ESR2 variation and ovarian cancer risk.

Leigh Pearce C, Near AM, Butler JL, Van Den Berg D, Bretsky P, Conti DV, Stram DO, Pike MC, Hirschhorn JN, Wu AH.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):393-6. doi: 10.1158/1055-9965.EPI-07-2512.

Supplemental Content

Support Center